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aBVF Predicts Knee OA Structural Progression
Predictor Range of
predictor
values
Proportion of
medial JSN
progression
OR for medial
JSN progression
Baseline aBVF (0.008 - 0.06) lowest quartile 12/121 (9.9%) Referent
(0.06 - 0.09) 11/117 (9.4%) 0.9 (0.4 - 2.2)
(0.09 - 0.13) 9/108 (8.3%) 0.8 (0.3 - 2.0)
(0.13 - 0.54) highest quartile 24/116 (20.7%) 2.4 (1.1 - 5.0)
p for trend ¼ 0.02
aBVF
change(per yr)
(-0.22 - -0.01) lowest quartile 7/112 (6.3%) Referent
(-0.01 - 0) 13/115 (11.3%) 2.0 (0.8 - 5.2)
(0 - 0.01) 12/114 (10.5%) 1.8 (0.7 - 4.9)
(0.01 - 0.18) highest quartile 24/116 (20.1%) 4.1 (1.7 - 10.0)
p for trend ¼ 0.002
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ARGS NEOEPITOPE, PRESUMABLY DERIVED FROM ADAMTS5 ACTIVITY,
IS ELEVATED IN SERUM AND URINE FROM OSTEOARTHRITIS PATIENTS
UNDERGOING KNEE REPLACEMENT
F.M. Germaschewski 1, L.R. Cooper 1, F. Liu 2, J. Larkin 2, S. Woodward 3,
A.-C. Bay-Jensen 4, M. Karsdall 4, C. Matheny 2. 1GlaxoSmithKline,
Stevenage, Herts, UNITED KINGDOM; 2GlaxoSmithKline, Philadelphia, PA;
3 Synarc, Paris, FRANCE; 4Nordic BioSci., Herlev, DENMARK
Purpose: Proteolytic degradation of aggrecan in articular cartilage is
a characteristic feature of osteoarthritis (OA). ADAMTS5-mediated
cleavage of aggrecan generates the 374ARGS neoepitope. The objective of
this study was to evaluate 374ARGS levels in variousmatrices from different
OA populations in contrast to human subjects and assess performance of
a sensitive target-speciﬁc immunoassay to facilitate the clinical develop-
ment of an ADAMTS5 inhibitor for the treatment of OA.
Methods:Matched sera and urine were collected from 20 healthy subjects
(13 women, 7 men) aged from 26 to 60 years (mean  SD: 43.28.4) and
from 20 subjects with knee OA (12women, 8 men aged from 49 to 77 years
(meanSD: 66.1 7.36). Matched serum, urine and synovial ﬂuid was
obtained from 19 subjects undergoing joint replacement for knee OA (15
women, 9 men) aged from 47 to 85 years (meanSD: 69.111.30). Diurnal
and inter-day variation (over 3 visits) was evaluated in the non-surgical OA
group. Serum and urine samples were collected on two visits for the
patients undergoing knee replacement with synovial ﬂuid taken only at
the time of surgery. Correlation to additional biomarkers including OSM,
COMP, PIIANP, CTX-II, CTX-1, OC, hsCRP, CPII, CIIM, AGNx-1 was assessed.
ARGS neoepitope was quantitated using a chemiluminescent Meso-Scale-
Discovery (MSD) immunoassaywhich had been optimised and validated in
serum, plasma, urine and synovial ﬂuid. In brief, a commercial anti-
aggrecan capture antibody was coupled with a sulfo TAG labelled GSK
antibody speciﬁc to the 374ARGS neoepitope (OA-1). 374ARGS standard was
generated by digestion of aggrecan with ADAMTS5 which was diluted in
appropriate matrices pre-depleted of 374ARGS. The lower limit of quanti-
ﬁcation was 1.37, 0.46, and 4.12 ng/mL in serum, urine, and synovial ﬂuid
respectively.
Results: The mean concentration of 374ARGS neoepitope in serum from
healthy subjects was 4.32.2ng/mL (range 0.9-8.9 ng/mL), 5.92.7ng/mL
(range 1.1-10.0) in non-surgical OA subjects, and 9.34.6ng/mL (range 2.0-
16.5) in the surgical OA patients. Synovial ﬂuid concentrations of 374ARGS
in the surgical OA patients were similar to serum levels in those patients
(meanSD: 8.285.29). 374ARGS levels were lower in urine than serum in
all subjects but showed a similar trend of elevation in the surgical OA
patients (meanSD 5.94.5 range 0.5-13.9) compared to 3.312.28
(meanSD) in non-surgical OA patients (range 0.5-8.7) and 2.73.3
(meanSD) in healthy subjects (range 0-10.8). Compared to healthy
subjects, both serum (p¼0.004) and urine levels (p¼0.008) of 374ARGS
were signiﬁcantly elevated in the surgical OA patients. No signiﬁcant
difference was seen between healthy and non-surgical OA subjects. No
signiﬁcant diurnal effect or inter-day variance was observed in urine or
serum. Serum levels of 374ARGS correlated positively with COMP and CTX-
II (p<0.05) but not with other markers (OSM, PIIANP, CTX-1, OC, hsCRP,
CPII, CIIM, AGNx-1).Conclusions: This study utilized a highly sensitive and robust assay to
provide an initial evaluation of 374ARGS neoepitope concentrations in
various matrices in OA patients and healthy volunteers. There was
a general trend for increasing 374ARGS neoepitope concentration in serum
going from healthy subjects to non-end stage knee OA patients to end
stage (knee replacement) knee OA. Additional studies are planned to
evaluate 374ARGS as a diagnostic tool to facilitate patient selection as well
as provide an early indication of the pharmacodynamic effects of an
ADAMTS5 inhibitor in clinical trials.
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GENES ASSOCIATED WITH OSTEOARTHRITIS IDENTIFIED BY
MICROARRAY-ANALYSIS OF WHOLE BLOOD SAMPLES LINK OA TO
APOPTOTIC PATHWAYS
Y.F. Ramos 1, S.D. Bos 1, N. Lakenberg 1, M. Kloppenburg 2,
P.E. Slagboom1,3, I. Meulenbelt 1. 1Dept. of Molecular Epidemiology, LUMC,
Leiden, NETHERLANDS; 2Depts. of Clinical Epidemiology and Rheumatology,
LUMC, Leiden, NETHERLANDS; 3Netherlands Genomics Initiative-sponsored
Netherlands Consortium for Hlth.y Aging (NGI-NCHA), Leiden, NETHERLANDS
Purpose: Recently, genome wide association (GWA) studies have been
performed and the ﬁrst consistent OA-susceptibility loci have emerged.
Nevertheless, additional insight about the molecular and cellular aspects
of osteoarthritis (OA) is necessary. Gene expression proﬁling of peripheral
blood cells may be a valuable tool for assessing signatures of differential
gene expression related to disease. In the current study, an extensive large
scale exploration of gene expressionwas performed in mononuclear blood
cells of distinct osteoarthritis (OA) cases of the GARP study and their age-
and disease-matched controls.
Methods: We used a subset of 108 samples from the GARP-study which
consists of Dutch sibling pairs with symptomatic and radiographic OA in
two or more joint sites of the hand, spine (cervical or lumbar), knee or hip.
As comparison we included 33 age-matched controls without any radio-
graphic or symptomatic OA in the indicated joints. RNA was isolated
speciﬁcally of mononuclear blood cells after Histopaque separation.
Microarray analysis was performed on Illumina Human HT-12_v3_Bead-
Chips after conﬁrming integrity of the RNA with lab-on-a-chip. Pathway
analysis was performed with the Database for Annotation, Visualization
and Integrated Discovery (DAVID) tool.
Results: Data obtained in this study showed high quality expression
proﬁles. After normalization, adjusting for sex and age and correcting for
multiple testing we found 567 probes representing 528 genes that showed
signiﬁcant differential expression between cases and controls. From these,
81 probes (79 genes) show a difference of 1.5 times or more (lowest P-
value ¼ 8.2*10-13). When the latter group of genes was used for gene
enrichment analysis in DAVID (GO-terms all Biological Pathways (BP_all)),
apoptosis was identiﬁed as a highly signiﬁcant pathway (P-value¼5.4*10-
3) due to differential expression of 13 genes herein. Notable in this pathway
was the differential expression of the well known apoptotic gene CASP3
which has also been linked to cartilage degradation in OA.
Conclusions: In this study, we have determined a distinctive gene
expression signature of blood from OA patients in comparison to age and
diseased matched controls. Interestingly, in this signature, genes involved
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S78in the apoptotic pathway were overrepresented. Currently, we are vali-
dating the data by RT-qPCR. Our exploration may be a valuable tool for
assessing genes underlying networks predicting susceptibility to OA or
marking the ongoing disease.
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EFFECT OF A 16 WEEKS WEIGHT LOSS PROGRAMME ON CARTILAGE
BIOMARKERS IN OBESE PATIENTS WITH KNEE OSTEOARTHRITIS:
A PROSPECTIVE COHORT STUDY
E.M. Bartels 1, R. Christensen 1,2, D. Heinegård 3, T. Saxne 3,
M. Henriksen 1, A. Bennett 4, S. Lohmander 3,2, H. Gudbergsen 1,
M. Boesen 1, H. Bliddal 1,5. 1 The Parker Inst., Copenhagen Univ. Hosp. at
Frederiksberg, Copenhagen F, DENMARK; 2 Inst. of Sports Sci. and Clinical
Biomechanics, Univ. of Southern Denmark, Odense M, DENMARK; 3Dept.s
of Clinical Sci. Lund, Lund Univ., Lund, SWEDEN; 4 IDS Nordic A/S, UK,
UNITED KINGDOM; 5 Faculty of Hlth.Sci., Univ. of Copenhagen, Copenhagen,
DENMARK
Purpose: Knee osteoarthritis (KOA) is a common disease where easily appli-
cable, well-deﬁned and objective tools for monitoring clinical improvement
following treatment are not clearly deﬁned; biomarkers could be such a tool.
Weight loss is a recommended treatment for obese KOA patients, and short-
term assessment of cartilage degradation is important. The aim of this study
was to follow changes in cartilage markers Serum Cartilage Oligomeric Matrix
Protein (S-COMP) and urine C-terminal telopeptide of collagen type II (U-CTX-
II), and bone marker urine C-terminal telopeptide of collagen type I (U-CTX-I),
over 16 weeks intensive weight loss in KOA patients.
Methods: 192 subjects from the outpatient clinic at Department of Rheu-
matology, Frederiksberg Hospital, Denmark were exposed to 16 weeks of
weight loss (the CAROTstudy). Patientswere over 50 years of agewith a body
mass index  30 kg/m2, and conﬁrmed KOA on standing semi-ﬂexed radio-
graphs. S-COMP, U-CTX-II and U-CTX-I were determined by ELISA. To assess
the symptomatic improvement, the change from baseline to 16 weeks in the
average score on four subscales of the Knee Injury and Osteoarthritis
Outcome Score (KOOS) _ pain, symptoms, function, and knee-related quality
of life (KOOS4; range of scores, 0 [worst] to 100[best]). The statistical analysis
was based on a general linear model, applying Analysis of Covariance
(ANCOVA) with a factor for sex, with BMI and age at baseline both applied as
covariates. Toassess thebivariate associationbetweeneachof thebiomarkers
with changes in body weight and KOOS4, Pearson Correlation Coefﬁcients
applied with a P-value 0.05 (two-tailed) indicating statistical signiﬁcance.
Results: 91% (175) of the patients completed the 16weeksweight loss scheme.
Themeanweight loss was 13.4 kg (95%CI: 12.5 to 14.4, P< .0001), mean loss of
fatmass11.2 kg (10.4 to11.9, P<.0001), andmaybeasmall (non-signiﬁcant) loss
in lean body mass (0.7 kg; P¼.089). By self-assessment, the patients showed
a signiﬁcant improvement of 10.0 on KOOS-4 (7.7 to 12.3, P<.0001). Looking at
biomarkers at the group level, S-COMP decreased signiﬁcantly with a mean of
1.1 U/l (0.7 to 1.5, P<.0001), while U-CTX-II increased with a mean of 63 ng/
mmol creatine (25 to 101, P¼.0013), and U-CTX-I increased with a mean of 66
mg/mmol creatine (46 to 86, P<.0001). On the individual participant level,
change in S-COMPwas correlated toweight change,with adecrease in S-COMP
withdecreasedweight (r¼-.16, P¼.03),whileU-CTX-II showednocorrelation to
weight loss (r¼.11, P¼.16). U-CTX-I increasedwithweight loss (r¼.22, P¼.0048).
U-CTX-II showedastrongcorrelation toKOOS-4,withdecreasingU-CTX-IIwith
improvement inKOOS-4 (r¼-.28, P¼.0002),while S-COMPandU-CTX-I did not
correlate to KOOS-4 (P>.097).
Conclusions: A weight loss over 16 weeks in obese knee osteoarthritis
patients causes a reduction in S-COMP concentration directly associated
with themagnitude of weight loss. Changes were also seen in U-CTX-II and
U-CTX-I, but only the latter was correlated to the weight loss magnitude.
This study was supported by The Oak Foundation, The Velux Foundation,
and The Cambridge Weight Plan.
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ASSOCIATIONS OF CTX-II WITH BIOCHEMICAL MARKERS OF BONE
TURNOVER RAISE QUESTIONS ON ITS TISSUE ORIGIN: DATA FROM
CHECK, A COHORT STUDY OF EARLY OSTEOARTHRITIS
W.E. van Spil, J.W. Bijlsma, S.C. Mastbergen, F.P. Lafeber. Univ. Med. Ctr.
Utrecht, Utrecht, NetherlandsPurpose: Biochemical markers (biomarkers) are proposed to reﬂect
certain metabolic pathways in health and disease. However, actual
molecular validity of biomarkers is often not deﬁnite. uCTX-II has been put
forward as a marker of collagen type II degradation being part of cartilage
degradation in osteoarthritis and is used as (surrogate) end point in
therapeutic trials. Here we present data that argue against this assumption
and warrant more cautious interpretation of uCTX-II levels.
Methods: uCTX-II, and the bone biomarkers uCTX-I, uNTX-I, sPINP and sOC
as well as the cartilagemarkers sCOMP, sCS846, and sPIIANPwere assessed
by ELISA in baseline samples of CHECK (Cohort Hip & Cohort Knee),
a cohort of 1002 individuals with early complaints of pain and/or stiffness
in knee and/or hip. Associations between biomarkers and between
biomarkers and demographics were investigated through multiple linear
regression analysis.
Results: uCTX-II was more strongly associated with bone markers than
with the cartilage markers, while the cartilage markers did not show such
strong associations with the bone markers. Moreover, both uCTX-II and
bone markers but not the other cartilage markers showed an abrupt
menopausal shift in woman at the age of 50-55 years, also when adjusted
for age and BMI.
Conclusions: The increased bone marker levels in postmenopausal
women are in accordance with the well-known increase in bone turnover
after menopause. The many similarities between uCTX-II and bone
markers could be attributable to a link between cartilage and bone
metabolism through metabolic and biomechanical mechanisms. However,
other cartilage markers were hardly associated with uCTX-II and did not
show such evident associations with bone markers. These data suggest
that uCTX-II has unique relations with bone markers as compared to other
cartilage markers and reﬂects bone rather than cartilage metabolism.
Accordingly, other authors have suggested osteoclastic resorption of
calciﬁed cartilage as the major origin of uCTX-II. More thorough molecular
validation of uCTX-II is required to better deﬁne its origin. Until then,
uCTX-II levels should be interpreted cautiously.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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THE ABILITY OF BIOCHEMICAL MARKERS TO REFLECT BURDEN AND
PROGRESSION IN (VERY) EARLY KNEE AND HIP OSTEOARTHRITIS:
DATA FROM CHECK
W.E. van Spil, N.W. Jansen, S.C. Mastbergen, J.W. Bijlsma, P.M. Welsing,
F.P. Lafeber. Univ. Med. Ctr. Utrecht, Utrecht, NETHERLANDS
Purpose: To investigate the ability of (combinations of) biochemical
markers (biomarkers) to reﬂect osteoarthritis (OA) burden and 5-year
progression in (very) early knee and hip OA. On the basis of systematic
review data it was hypothesized that biomarkers of cartilage and synovial
metabolism would appear superior to markers of bone metabolism.
Methods: Eleven biomarkers (Cartilage: uCTX-II, sCOMP, sPIIANP, sCS846.
Bone: uCTX-I, uNTX-I, sOC, sPINP. Bone/cartilage: sC1,2C. Synovial tissue:
sHA, sPIIINP) were assessed by ELISA or RIA in baseline samples from
CHECK (Cohort Hip & Cohort Knee), a prospective cohort of 1002 indi-
viduals with symptoms of (very) early knee and/or hip OA.
Knee and hip radiographs were obtained at baseline and after 2 and 5
years. OA burdenwas expressed as the summed Kellgren & Lawrence (K&L)
score for knees and hips at baseline. OA progression was expressed as the
area under the curve (AUC) of summed K&L scores.
Associations were investigated through multiple linear regression.
Biomarkers were used individually as well as in combinations of stan-
dardized scores (Z-scores). sCOMP was used in combination with cartilage
as well as synovial biomarkers.
Results: Data were complete for approximately 800 participants at base-
line and 725 participants at all time points. Baseline summed K&L grades 0,
1, 2, 3, and 4 were present in 33.9, 26.8, 24.0, 9.6, and 5.7% of participants,
respectively (maximum K&L grade¼1 for individual joints). AUC of sum-
med K&L grades between baseline and 5 years were 0, 1.5-3.0, 3.0-5.5, and
5.5-17.5 for 39.0, 18.3, 22.5, and 20.1% of participants, respectively.
At baseline, uCTX-II, sCOMP, sPIIANP, sHA, and sPIIINP showed statistically
signiﬁcant associations with the summed K&L score (maximum stan-
dardized betas 0.183, P¼0.000 and 0.161, P¼0.000 for sHA and uCTX-II,
